Why Eli Lilly and Company (LLY) stock moved
No significant move on Nov 20, 2026 (−0.3%, close-to-close). Latest notable session: Nov 9, 2026.
Why Eli Lilly and Company (LLY) rose 4.3% on November 9, 2026
Eli Lilly and Company (LLY) rose 4.3% on November 9, 2026, closing at $1,411.95 versus $1,354.00 the prior session (close-to-close, from daily closes). Following positive clinical trial results and a bullish analyst upgrade. Foundayo, Lilly's oral weight-loss drug candidate, met its primary endpoint in a late-stage sleep apnea study, reducing breathing interruptions by up to 44% at 52 weeks (finance.yahoo.com). Source: Yahoo Finance.
Eli Lilly shares rose 4.28% to $1,411.97 following positive clinical trial results and a bullish analyst upgrade. Foundayo, Lilly's oral weight-loss drug candidate, met its primary endpoint in a late-stage sleep apnea study, reducing breathing interruptions by up to 44% at 52 weeks (finance.yahoo.com). Jefferies simultaneously raised its price target to $1,700, citing strong oral drug economics and international expansion opportunities. Canada's positive reimbursement recommendation for Kisunla (donanemab) for Alzheimer's treatment added to momentum in the core weight-loss franchise.
What to watch next: Earnings on 2027-02-03 (date unconfirmed; consensus EPS $11.20). Monitor regulatory filings for Foundayo's potential FDA submission timeline and track reimbursement decisions in major markets for Kisunla and Zepbound.
Earlier sessions that moved LLY
- −3.8%On the same day, the company reported strong earnings and raised guidance, while announcing pivotal Phase 3 trial results for retatrutide showing substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity.
- +3.2%Eli Lilly reported third-quarter 2026 earnings that handily beat consensus, with revenue of $24.4 billion (up 39% year-over-year) and adjusted EPS of $7.48 versus estimates of $5.60, driven by blockbuster diabetes and weight-loss drug sales—Mounjaro at $10.7 billion and Zepbound at $5.35 billion quarterly.
- +6.6%Eli Lilly reported third-quarter revenue of $24.4 billion (+39% YoY), beating consensus of $22.58 billion, and adjusted EPS of $7.48, far exceeding the $5.68 consensus, driven by blockbuster demand for GLP-1 drugs Mounjaro and Zepbound (Barron's, Zacks). Read the October 29, 2026 analysis →
- +2.8%Following earlier momentum that saw the stock jump as much as 5.1% during the session (finance.yahoo.com).
- +3.5%Amid pre-earnings positioning ahead of the company's October 29 Q3 results (web_catalyst).
- +3.5%Driven by strong institutional rotation into large-cap healthcare and sustained bullish momentum around its metabolic and weight-loss pipeline, including retatrutide and oral GLP-1 candidates, ahead of Q3 2026 earnings scheduled for October 29 (web catalyst).
- +3.6%No specific catalyst event or news catalyst was identified in today's trading session; the gain follows recent analyst commentary highlighting LLY's revenue growth outpacing major pharma peers despite premium valuation (247wallst.com, 2026-10-13), though volume data remains unreliable this early in the session.
- +2.7%Driven by momentum in its GLP-1 weight-loss franchise (Mounjaro, Zepbound) and CEO David Ricks' commentary on aggressive M&A plans to expand into infectious disease and neuroscience, according to web sources.
Eli Lilly and Company (LLY) shares fell 0.3% to $1,347.11 as of November 21, 2026, a slight decline from the prior close of $1,351.12. BestStocks flagged the session as a major change for LLY. The move is tied to company news. Below, we break down what changed for LLY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Lilly's Foundayo demonstrated 44% reduction in obstructive sleep apnea severity in clinical trial data. Expands Foundayo's addressable market beyond weight loss, potentially supporting premium pricing and recurring revenue growth.
What it means for Eli Lilly and Company investors
For Eli Lilly and Company investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Eli Lilly reported third-quarter revenue of $24.4 billion (+39% YoY), beating consensus of $22.58 billion, and adjusted EPS of $7.48, far exceeding the $5.68 consensus, driven by blockbuster demand for GLP-1 drugs Mounjaro and Zepbound (Barron's, Zacks); Positive price momentum. Weighing against that: Negative session, down 0.3%; New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in LLY's fundamentals. Wall Street's consensus price target sits at $1,442.44, implying +7.1% upside from $1,347.11. BestStocks rates the overall signal quality weak (38/100). With earnings roughly 74 days out, the next report is the most likely near-term test of the move.
LLY price reaction
LLY last traded at $1,347.11, down $4.01 (-0.30%) from the previous close of $1,351.12. The session traded on 1.4× average volume (normal), so participation was unremarkable. Its healthcare peer group moved a median +0.9% over the same stretch, leaving LLY behind the group by 1.2 points. Over the past month the stock has ranged between $1,270.75 and $1,443.50, and it currently sits about 44% of the way up that band.
Bullish and bearish analyst opinions on Eli Lilly and Company (LLY)
The consensus analyst price target on Eli Lilly and Company (LLY) is $1,442.44, 7.1% above the recent $1,347.11. Over the past 90 days analysts logged 0 upgrades, 19 maintains, and 0 downgrades. Here is how the bullish and bearish cases on LLY line up.
The bullish case
- Wall Street's consensus price target of $1,442.44 implies +7.1% upside from $1,347.11.
- The Street's most bullish target is $1,650.00 (+22.5%).
- Eli Lilly reported third-quarter revenue of $24.4 billion (+39% YoY), beating consensus of $22.58 billion, and adjusted EPS of $7.48, far exceeding the $5.68 consensus, driven by blockbuster demand for GLP-1 drugs Mounjaro and Zepbound (Barron's, Zacks).
- Positive price momentum.
The bearish case
- The most bearish analyst target is $940.00 (-30.2%).
- Negative session, down 0.3%.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for LLY
In-depth LLY event analyses
Frequently asked questions about LLY
Why did Eli Lilly and Company (LLY) stock move?
Eli Lilly and Company (LLY) rose 4.3% on November 9, 2026, closing at $1,411.95 versus $1,354.00 the prior session (close-to-close, from daily closes). Following positive clinical trial results and a bullish analyst upgrade. Foundayo, Lilly's oral weight-loss drug candidate, met its primary endpoint in a late-stage sleep apnea study, reducing breathing interruptions by up to 44% at 52 weeks (finance.yahoo.com). Source: Yahoo Finance.
How much did LLY stock fall?
LLY lost 0.30% ($4.01) versus the prior close of $1,351.12, last trading at $1,347.11 on 1.4× average volume.
When is Eli Lilly and Company's next earnings date?
LLY's next earnings report is estimated for 2027-02-03 — about 74 days away.
What is the analyst price target for LLY?
The consensus analyst price target for LLY is $1,442.44, about 7.1% above the current $1,347.11. Over the past 90 days, analysts recorded 0 upgrades, 19 maintains, and 0 downgrades.
Is the LLY move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median +0.9% against LLY's -0.3%. LLY ranks top 6 of 7 peers.
How BestStocks tracks LLY
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for LLY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
